Onkure Therapeutics, Inc. (OKUR) - Form 8-K Summary
Business Context and Reporting Period
Onkure Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 12, 2026. The filing serves to announce the issuance of a press release detailing financial results for the quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are detailed in the text of this filing. The document solely references the availability of the Q4 and full-year 2025 results in the attached exhibit.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01, including the attached press release, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are enumerated in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial figures.
- Verify the company's cash position and runway given the lack of revenue disclosure in the 8-K text.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.
- Check for any subsequent filings that may incorporate the press release data by specific reference.